Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Park K, Sabari JK, Haura EB, Shu CA, Spira A, Salgia R, Reckamp KL, Sanborn RE, Govindan R, Bauml JM, Curtin JC, Xie J, Roshak A, Lorenzini P, Millington D, Thayu M, Knoblauch RE, Cho BC.
Park K, et al.
Lung Cancer. 2023 Apr;178:166-171. doi: 10.1016/j.lungcan.2023.02.008. Epub 2023 Feb 15.
Lung Cancer. 2023.
PMID: 36868177
Free article.